{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:55:48Z","timestamp":1781510148430,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.berh.2026.102141","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:41:05Z","timestamp":1775684465000},"page":"102141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T-cell therapy \u201cLiving drugs\u201d in systemic lupus erythematosus"],"prefix":"10.1016","volume":"40","author":[{"given":"Leila","family":"Khalili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9763-8209","authenticated-orcid":false,"given":"Alberto","family":"Nordmann-Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-5023","authenticated-orcid":false,"given":"Anca","family":"Askanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2026.102141_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/cells15030212","article-title":"Gene and cell therapy in regenerative medicine","volume":"15","author":"Rizvanov","year":"2026","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.berh.2026.102141_bib2","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.berh.2026.102141_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.berh.2026.102141_bib4","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-Cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.berh.2026.102141_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.berh.2026.102141_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2026.102141_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.berh.2026.102141_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.berh.2026.102141_bib9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.clml.2017.07.007","article-title":"Chimeric antigen receptor T-Cell therapy for chronic lymphocytic leukemia: a narrative review","volume":"17","author":"Mato","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.berh.2026.102141_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912366","article-title":"Prejudice? The value of Chimeric Antigen Receptor (CAR) T-Cell therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"issue":"9","key":"10.1016\/j.berh.2026.102141_bib11","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.berh.2026.102141_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-Cell therapy by site of care among patients with relapsed or refractory large B-Cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.berh.2026.102141_bib13","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.berh.2026.102141_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1325209","article-title":"Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation","volume":"14","author":"Netsrithong","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102141_bib15","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","author":"Li","year":"2025","journal-title":"Med N Y N"},{"issue":"25","key":"10.1016\/j.berh.2026.102141_bib16","first-page":"S2666","article-title":"Under the hood: evidence-based review of allogeneic chimeric antigen receptor T cells for hematologic malignancies","author":"Cheema","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2026.102141_bib17","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2023-181919","article-title":"Expansion, persistence and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-Targeted CAR gamma Delta T cell therapy, in patients with relapsed\/refractory aggressive B-Cell non-hodgkin\u2019s lymphoma","volume":"142","author":"Moreno","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.berh.2026.102141_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell therapy: promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.berh.2026.102141_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.berh.2026.102141_bib20","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.berh.2026.102141_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12951-024-02630-1","article-title":"Steering the course of CAR T cell therapy with lipid nanoparticles","volume":"22","author":"Khawar","year":"2024","journal-title":"J Nanobiotechnol"},{"issue":"15","key":"10.1016\/j.berh.2026.102141_bib22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2026.102141_bib23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102141_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102141_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of relmacabtagene autoleucel (Relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"Supplement 1","key":"10.1016\/j.berh.2026.102141_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ard.2025.05.056","article-title":"OP0032 treatment of refractory systemic lupus erythematosus with off-the-shelf iPSC-derived Anti-CD19 CAR T-cell therapy","volume":"84","author":"Sandhu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102141_bib27","author":"Schett"},{"issue":"12","key":"10.1016\/j.berh.2026.102141_bib28","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"10.1016\/j.berh.2026.102141_bib29","first-page":"1629","article-title":"CAR T-Cell therapy in autoimmune disease","volume":"390","author":"De Benedetti","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2026.102141_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transp J Am Soc Blood Marrow Transp"},{"issue":"9","key":"10.1016\/j.berh.2026.102141_bib31","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.berh.2026.102141_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ard.2025.05.101","article-title":"OP0079 clinical, cellular kinetics, pharmacodynamics and biomarker data up to 12 months after YTB323 (Rapcabtagene autoleucel), a rapidly manufactured CD19 CAR-T therapy, from an open-label, phase 1\/2 study in severe refractory SLE","volume":"84","author":"Morand","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"10.1016\/j.berh.2026.102141_bib33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-Cell lymphoma after CAR T-Cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102141_bib34","first-page":"1","article-title":"Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA\u2019s conclusions from the evaluation of 38 suspected cases","volume":"22","author":"Berg","year":"2025","journal-title":"Gene Ther"},{"issue":"20","key":"10.1016\/j.berh.2026.102141_bib35","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-Cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:46:15Z","timestamp":1781509575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521694226000264"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102141","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy \u201cLiving drugs\u201d in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102141"}}